Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection (NIRVANA)
NIRVANA: NIcotinamide Riboside in SARS-CoV-2 pAtients for reNAl Protection
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10029-6574
- Icahn School of Medicine at Mount Sinai
-
-
Texas
-
San Antonio, Texas, United States, 78229
- The University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, United States, 78229
- University Health Systems
-
-
Washington
-
Seattle, Washington, United States, 98104
- Harborview Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Provision of signed and dated informed consent form from a participant or legally authorized representative (LAR);
- Male or female, >18 years old;
- Hospitalized participants with a laboratory diagnosis of COVID-19 infection
- Evidence of persistent AKI as defined by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines (Table 3);
- Willing to adhere to the study intervention regimen;
Exclusion Criteria:
- Hypersensitivity to nicotinamide riboside (NR);
- Pregnant or lactating women confirmed with positive laboratory pregnancy tests as per local requirements;
- eGFR <15 mL/min/1.73 m2 as per the Chronic Kidney Disease Epidemiology Collaboration equation at admission lab;
- Maintenance renal replacement therapy or initiation of renal replacement therapy before randomization
- Currently on NR or nicotinamide or vitamin B3 (niacin) supplementation (multivitamins are allowed);
- Concomitant cirrhosis of liver or acute liver failure;
- Any medical history or condition that might, in the opinion of the attending physician, put the participant at significant risk if he/she were to participate in the trial;
- Individuals with kidney transplant;
- Individuals with blood platelet count <100,000/microL
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo Group
Placebo capsules will be administered 2 capsules twice daily for 10 days
|
Placebo capsule containing inert ingredient
Other Names:
|
|
Experimental: Nicotinamide Riboside Group
Nicotinamide riboside 250mg capsules will be administered 2 capsules twice daily for 10 days
|
250 mg Nicotinamide riboside capsules
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Occurrence of Thrombocytopenia
Time Frame: Baseline to 10 days
|
Number occurrences of thrombocytopenia defined as >25% decline in blood platelet count from baseline.
|
Baseline to 10 days
|
|
Change in Whole Blood NAD+ Level
Time Frame: Baseline to 10 days
|
Measure of NAD+ level in whole blood from treatment beginning to end
|
Baseline to 10 days
|
|
Number of Participants With Adverse Events of Grade 3 or Higher
Time Frame: Baseline to 10 days
|
Safety of NR in hospitalized patients with COVID-19 and AKI (defined as adverse event of Grade 3 or higher).
Not every grade 3 event was considered to be serious.
|
Baseline to 10 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Proteinuria
Time Frame: 30 days to 90 days
|
Measurement of change in proteinuria at 30-90 days post randomization
|
30 days to 90 days
|
|
Change in Area Under the Curve (AUC)
Time Frame: Baseline to 10 days
|
To determine the effect of NR on changes in AUC serum creatinine from baseline during the 10-day intervention
|
Baseline to 10 days
|
|
Effect of NR on Major Adverse Kidney Events (MAKE)
Time Frame: 30 days to 90 days
|
Number of occurrences of MAKE defined as doubling of serum creatinine, the initiation of long-term dialysis, or death from any cause.
|
30 days to 90 days
|
|
Change in Estimated Glomerular Filtration Rate (eGFR)
Time Frame: 30 days to 90 days
|
Measurement of change in eGFR at 30-90 days post randomization
|
30 days to 90 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Kumar Sharma, MD, UT Health San Antonio
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Kidney Diseases
- Urologic Diseases
- Renal Insufficiency
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- COVID-19
- Acute Kidney Injury
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Antimetabolites
- Micronutrients
- Hypolipidemic Agents
- Lipid Regulating Agents
- Vitamins
- Vitamin B Complex
- Nicotinic Acids
- Niacinamide
- Niacin
Other Study ID Numbers
Other Study ID Numbers
- HSC20200914H
- 3UH3DK114920-04S2 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.